Clinical Trials Browser

Withdrawn × NIH × Neoplasms, Plasma Cell × Clear all

NCT01647165 2019-12-12

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00085345 2013-07-10

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell